The authors claimed that GpS, especially gypenoside XL, could target peroxisome proliferator‐activated receptor alpha (PPARα), the expression of which was downregulated in alcoholic fatty liver disease and NAFLD patients in the liver. Here, NBEAL2 is linked to metabolic dysfunction-associated steatotic liver disease.